Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease
Status:
Completed
Trial end date:
2018-06-14
Target enrollment:
Participant gender:
Summary
To determine whether treatment with ustekinumab will alter the ratio of T Regulatory Cell
(Treg)/total cluster of differentiation 4 (CD4)+ cells in peripheral blood at day 30
post-hematopoietic cell transplantation (HCT).
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute